Curus was founded in 2016. 

The team initiated and progressed a novel drug development program to a Phase 2a Randomised Controlled Trial, which received Human Ethics Committee Approval (HREC) at three treatment sites in Australia for a pediatric population with Drug-Resistant Epilepsy.

During the collaboration with the University of Canberra, the team initiated a clinical study of a new therapy in combination with standard care as a novel strategy for treating patients with Melanoma.

The team has extensive experience in clinical research, clinical studies, funding start-up seed rounds, as well as global pre-IPO and IPO financing.

Curus incorporates input from clinical researchers, medical practitioners, industry, and the neurodiverse community. It is continually striving to evolve.